Investigational drug · Phase 2
Palacaparib
Also called: AZD9574
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
2
Any phase or sponsor naming "Palacaparib"
First trial start
2021
Oct 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Palacaparib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Prostate Cancer
- Ovarian Cancer
- Endometrial Cancer
- Breast Cancer
- Biliary Tract Carcinoma
- Squamous Non-Small Cell Lung Cancer
- Lung Adenocarcinoma
- Lung Squamous Cell Carcinoma
- Advanced Solid Malignancies
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Ovarian cancer · Endometrial cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Palacaparib" as an intervention, largest first.
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05797168 · 622 participants (planned) · Start Jun 5, 2023 · Primary completion Aug 4, 2028
Drug: Torvutatug samrotecan; Saruparib and 4 more · For: Ovarian Cancer; Lung Adenocarcinoma; Endometrial Cancer and 1 more
Sites: Duarte, California; Irvine, California; La Jolla, California · 60 sites in all
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07590934 · 152 participants (planned) · Start Jun 3, 2026 · Primary completion Sep 25, 2029
Drug: AZD2265 (FPI-2265); Palacaparib (AZD9574) and 2 more · For: Metastatic Prostate Cancer
Sites: Duarte, California; Encino, California; South Pasadena, California · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- PARP-1 selective inhibitors: A new direction in drug discovery to improve the therapeutic index of PARP-targeted cancer therapy.
Elkafoury EM, El-Moselhy TF, El-Hamamsy MH, et al. · Drug Discov Today 2026
- Preclinical Evaluation of [18F]Itareparib, a brain penetrant PARP1-selective radioligand, in Glioma Rat Model and Nonhuman Primate.
Tan PW, Hernandez-Martin N, Esposito-Zapero C, et al. · bioRxiv 2026
- Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models.
Ruiz-Gonzalez CE, Singh M, Masias-Leon Y, et al. · Nat Commun 2026
- From DNA repair to neurodegeneration: PARP1 mechanisms and inhibitor strategies in Alzheimer's disease.
Banjare P, Patel R · DNA Repair (Amst) 2026
- Structural Determinants of PARP1 Selectivity from Molecular Dynamics Analysis of PARP1 and PARP2 Complexes.
Shkil DO, Chesnokova NA, Ivashchenko AA, et al. · Molecules 2026
- A novel 18 F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1.
Patel JS, Zhou X, Chen J, et al. · bioRxiv 2025
Also in development for Metastatic Prostate Cancer
- FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials
Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- AZD2287Imaging agentPhase 22 trials
AstraZeneca · Metastatic Prostate Cancer
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- AZD0516Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD0754Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD8359Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- GDC-1261Phase 21 trial
Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.